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Abstract
Diabetes mellitus, a disease with abnormally high level of blood glucose, can cause a
wide range of chronic complications that affect almost every parts of the body. The major
goal  of  diabetes  treatments  is  to  control  elevated  blood  glucose  without  causing
abnormally  low  levels  of  blood  glucose.  Despite  islet  transplantation  provided
endogenous insulin secretion in individuals with diabetes, the scarcity of cadaveric
donors for pancreatic β-cell still remains a major obstacle. In this regard, the needs for
an unlimited supply for  cell  replacement  strategy have led to  explore the way of
generating insulin-producing cells to use in the disease treatment. Human embryonic
stem cells (hESCs) offer a source to produce the desired kind of cell. Currently, several
researchers achieved insulin-producing cells from hESCs using a multistep differentia‐
tion  protocols,  growth  factors,  and/or  chemical  compounds.  In  this  review,  we
summarized the hESCs derivation, culture methods, and characteristics of hESCs. We
also  emphasized  on  the  current  methods  for  direct  differentiation  of  hESCs  into
embryoid bodies (EBs) and toward insulin-producing cells, characterization of these
insulin-producing cells, and the limitation of hESCs. Since the discovery of induced
pluripotent stem cells (iPSCs), which have similar properties to hESCs but less ethical
issues than hESCs, can be created directly from somatic cells that hold great promise as
the  therapeutic  source  for  developing  cell-based  therapy.  Herein,  the  methods  to
produce  iPSC-derived  insulin-producing  cells  are  also  discussed.  Moreover,  the
encapsulation technology which is a powerful tool for accelerate hESCs and iPSCs
applications in medicine which provide a new avenue for diabetes treatment in the
future is also included in this review. Understanding the basic knowledge of hESCs and
iPSCs,  their  differentiation capability toward insulin-producing cells  will  stimulate
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more therapeutic value of hESCs and iPSCs for diabetic treatments, drug screening, and
regenerative medicine.
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1. Introduction
Diabetes mellitus is one of the most common chronic diseases that threaten the health and health
economics worldwide [1–3]. The disease and cases management interventions improve short-
and long-term health, and/or economic outcomes of patients are improving health and quality
of their lives. General treatments include weight reduction, a diabetes diet, and exercise which
are used to control diabetes [4, 5]. When these treatments fail to control the elevated blood
glucose, oral medications and insulin injection therapy will be applied in the treatment strategy,
respectively. Insulin therapy has the potential to improve symptoms, enhancing quality of life
and provide a sense of well-being [6–8]. However, the intensive insulin treatment can cause
hypoglycemia  [9–11].  Therefore,  transplantation  of  high effective  insulin-producing cells
containing physiological regulation of blood glucose level is critical choice of treatment. At
present, there are three major cell-based therapy approaches to restore insulin-producing cells
in diabetes patients: 1) direct transplantation of donor islet and pancreatic cells to patient 2)
activation pancreatic progenitors residing in islet mass into insulin-producing cells (neogene‐
sis) and transplantation, and 3) stem cell approach by differentiation pluripotent stem cells into
insulin-secreted cells and then transplantation. The direct transplantation of islet cells and
neogenesis methods have demonstrated normoglycemia in the absence of exogenous insulin
therapy [12–14]. Nevertheless, the limitations of islet cell replacement are the following factors:
non-functioning of isolated islets, the small number of transplanted islets, the immunogenici‐
ty of isolated islets lead to immune rejection, transplantation to inappropriate sites, recur‐
rence of auto-immunity in the transplanted islets, and immunosuppression [15–18]. The third
method, stem cell approach: Pluripotent stem cells including hESCs and iPSCs are the main
targets for insulin-producing cell induction. These two sources of stem cells could provide
limitless sources of cells for pancreatic β-cell replacement strategy. Therefore, these research
areas have led researchers to explore the way of generating effective insulin-producing cells for
diabetes treatment. In addition, the hESCs and iPSCs contain the higher differentiation capacity
than adult stem cells [19–21].
Herein, we review the current knowledge of hESCs and iPSCs, followed by the directed
differentiation of these cells toward the functional insulin-producing cells. In addition, the
encapsulation technology, a powerful tool for accelerate hESCs and iPSCs applications in
medicine, is also included in this review. We also summarize and discuss evidence that both
hESCs and iPSCs are promising cell sources for future diabetes treatment.
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2. Human embryonic stem cells
2.1. Derivation, culture, and characterization of hESCs
In the early era of hESCs research, the hESCs are isolated from the inner cell mass (ICM) of
blastocyst-stage embryos by immunosurgery or mechanically methods. However, this process
involves with animal-derived substances such as mouse antibodies and guinea pig comple‐
ment [22, 23]. Alternatively, the use of Tyrode’s acid for the removal of zona pellucida and
mechanical isolation of ICM can serve as a potentially useful method for the establishment of
hESCs line in the present time. Indeed, this technique also implies that the blastocyst could
not contact with animal-derived pronase, antibodies, and complement factors [22]. The hESCs
lines can be maintained in an undifferentiated or pluripotency state in vitro for prolonged
periods of time. The potential of hESCs to differentiate into representing ectoderm, meso‐
derm, and endoderm derivatives has generated the possible use of hESCs in therapeutic
applications [24]. The derivation process involves culturing of the ICM of blastocyst stage,
induce to proliferate and differentiate into desired cell types [25]. The first successful deriva‐
tion of hESCs was isolated from the ICM of human blastocyst and placed on mitotically
inactivated murine feeder cells [26].
There are several methods have been reported for culture of undifferentiated hESCs in vitro
such as culture the undifferentiated hESCs on feeder layers, for example, mouse embryonic
fibroblast (MEF) or laminin- or Matrigel-coated-plastic surface with MEF conditioned
medium. However, these methods possibly transfer harmful animal pathogens to human
transplant recipients in clinical application [27]. Therefore, human feeder layers are used for
hESCs culture instead, for example, human adult marrow cells, human fetal muscle (FM),
human adult skin (AS), commercial human fetal skin (FS; D551/CCL-10, American Type
Culture Collection [ATCC]), human adult uterine endometrial cells (hUECs), human adult
breast parenchymal cells (hBPCs), and embryonic fibroblasts (hEFs). They are capable to
support undifferentiated stage and proliferation state of hESCs [28–31]. Conditioned medi‐
um from hESCs-derived fibroblasts (hESC-dFs) also efficiently supports growth of hESCs in
feeder-free culture systems [32]. Moreover, a three-dimensional (3D) porous natural poly‐
mer scaffolds (chitosan and alginate) effectively support self-renewal of hESCs without the
need of feeder cells or conditioned medium [33]. Recent study has demonstrated that a defined
engineered 3D microfiber system allows adequate propagation and cryopreservation of hESCs
under feeder-free chemically defined conditions [34]. However, these culture conditions still
have the ingredients from animal such as fetal bovine serum (FBS) and bovine albumin that
contain in culture medium. For the clinical potential in cell replacement therapy, differentiat‐
ed cells from hESCs should be cultured in xeno-free systems [27, 31]. Interestingly, Chen et al.
reported that the suspension culture system under defined and serum-free conditions provides
a powerful approach for scale-up expansion of hESCs. It was demonstrated that cell banks of
several hESCs lines are generated from this system under current good manufacturing
procedures (cGMP) or cGMP-equivalent conditions [35].
Characterization of hESCs lines can be achieved by both cellular and molecular analysis.
Cellular characterizations can be determined by (1) morphologies of hESCs colonies: form flat
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and compact colonies with distinct cell borders, (2) morphologies of hESCs have a high ratio
of nucleus to cytoplasm and have prominent nucleoli, (3) the hESCs exhibit high levels of
telomerase activity and show normal karyotype, (4) most of the cells can be subcultured after
freezing, thawing, and replating, (5) the cells can be differentiated into a variety of cell types
both in vitro and in vivo conditions, and (6) the cells can generate teratoma in animal model or
in vivo. The general molecular properties of hESCs lines can be examined by the expression of
several transcripts, for example, the stage-specific antigens (SSEA-3 and SSEA-4), the glyco‐
proteins tumor recognition antigen (TRA-1-60, TRA-1-81 and TRA-2-54), germ cell tumor
marker (GCTM-2), trophoblast giant (TG343 and 30), cluster of differentiation (CD9 and 133),
Octamer-4 (Oct4), Nanog, SRY-box-containing gene 2 (Sox2), teratocarcinoma-derived growth
factor 1 (Tdgf1), left–right determination factor 2 (LeftyA), RNA exonuclease 1 (Rex-1), Stellar,
Dazl, Nanos 1, pumilio gene (Pum 1 and 2), growth differentiation factor-3 (Gdf3), thymus cell
antigen 1 (Thy-1), and alkaline phosphatase [25, 36]. Other markers that are common to
characterize hESCs are following: SSEA-3, SSEA-4, TRA-1-60, TRA-1-81, Oct4, and alkaline
phosphatase. Nevertheless, there are differences between hESCs in their pluripotency or the
genetic profile under the same conditions, their potential for large-scale culture and growth
under feeder-free protocols, or their ability to form teratoma after injection into severe
combined immunodeficiency (SCID) mice. Moreover, their capacity to differentiate into
different cell types under in vitro conditions is variable [25, 36]. It is important to note that the
difference in various hESCs lines is useful for the scientists to choose the appropriate hESCs
line for their research.
2.2. Differentiation of hESCs into embryoid bodies (EBs) and definitive endoderm (DE)
To differentiate hESCs into particular cell lineages in vitro, the formation of embryoid bodies
(EBs) represents an important step to generate three germ layers; ectoderm, mesoderm, and
endoderm. The EBs will be then derive into tissue-specific progenitor cells and toward the
desire final differentiated lineages. It should be noted that hESCs are able to differentiate
through EBs parallels embryonic development due to the EBs recapitulates events during
embryogenesis [37]. The use of EBs to produce a variety of desired cell types represents an
exciting approach for therapeutic applications.
For the production of EBs, several methods have been designed. The first method: Methylcel‐
lulose (MC) method developed to form EB from single embryonic stem cell but has limita‐
tion to use EBs for medical application due to the contamination of methylcellulose. The second
method, hanging drop (HD) method has been widely used to generate EBs, and further
differentiate into a variety of cell types can be applied into other xenofree or chemically defined
medium culture protocols that suitable for human therapeutic applications. However, it is a
troublesome multiple steps methods. Moreover, it is hardly exchange that the medium for a
drop and the observations of forming EBs in drops by direct microscopic is difficult [38].
Therefore, the third method has been developed called suspension culture method—the
obtained EBs tends to be more heterogeneous in size and shape because their self-organized
aggregation in culture. The heterogeneity of EBs structures may influence cell fate differen‐
tiation [38, 39].
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In fact, improvement of the definitive endoderm (DE) layer development will increase the
successful rate of insulin-producing cell generation from pluripotent stem cells. Therefore,
there are several factors have been used to activation of DE formation, for example, activin A,
GDF8, Wnt3a, bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs),
inhibition of PI3K/Akt, and chemical inhibition of GSK3β [40]. In addition, collagen type 1
could improve the differentiation of hESCs into definitive endoderm [41].
2.3. Differentiation of hESCs into insulin-producing cells
At present time, cell-based therapy for diabetes is mostly target to type I diabetes. It has been
described that islet-like clusters derive hESCs differentiation can be achieved in multistep
procedures (nestin-positive protocol): (i) formation of EBs (stage 1), (ii) selective differentia‐
tion of cell populations expressing nestin using fetal calf serum depletion and culture with
ITSF (stage 2), (iii) proliferation and maintenance of precursor cells (stage 3), and (iv) the
differentiation induction and maintenance of insulin-positive cells (stage 4). The resultant cells
are positive for dithizone (DTZ), a zinc-chelating agent known to selectively stain pancreatic
β-cells, and are immunoreactive for antibodies against insulin, glucagons, and C-peptide.
Insulin and other pancreatic β-cell-related genes such as glucagon, somatostatin, KIR6.2 and
SUR1, IAPP, Isl1, PC1/3, PC2, GK, Nkx6.1, GLUT2, and Pax4 are expressed in the differenti‐
ating cells. The results indicated that differentiated cells can express genes involved in the β-
cell differentiation pathway [42].
Moreover, insulin-producing islet-like clusters (ILCs) are generated from hESCs according to
the method (definitive endoderm-based protocols) developed by Jiang and colleagues [43]
who culture hESC lines under feeder-free conditions and direct differentiation toward ILCs
by using a multistep, serum-free protocol. The 36-day differentiation protocol consists of four
stages which included definitive endoderm induction (stage 1), pancreatic endoderm
formation (stage 2), endocrine induction (stage 3), and islet-like clusters maturation (stage 4).
The hESCs generate definitive endoderm coexpressing CXCR4 and Sox17, and CXCR4 and
Foxa2 when treated with sodium butyrate and activin A. The Pdx1-expressing pancreatic
endoderm is then induced by the addition of bFGF, EGF, noggin, and B27 supplement.
Following withdrawal of bFGF, these cells are allowed to develop pancreatic endocrine cells.
Gene expression analysis shows that pancreatic endoderm cells also start to express other
pancreas-related genes such as HlxB9, Ptf1a, Ngn3, and Nkx6.1. Upon further differentiation
of Pdx1-positive cell clusters to day 36, immunocytochemical-staining data demonstrated that
the C-peptide-, glucagon-, and somatostatin-positive cells were predominantly localized in the
small bud-like clusters as well as in some of the smaller ILCs. In addition, the ILCs generat‐
ed by this protocol are able to secrete C-peptide in response to 20 mM glucose [43].
Based on the differentiation protocol, the nestin-positive progenitor-based and definitive
endoderm-based protocols are successful in generating insulin-producing cells from hESCs.
However, there is still some debate on the therapeutic potential between the cells obtained
from these two protocols. Therefore, other approaches are developed. Bruin and colleagues
implemented an approach in which hESCs were differentiated into fetal-like pancreatic cells
in vitro. Taking an approach, this group set out to replace activinA/wnt3A with GDF8/GSK3β
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inhibitor to enhance efficiency of definitive endoderm production. This study achieved to
generate insulin-producing cells and also revealed several key features of polyhormonal
insulin-positive cells that differ from mature pancreatic β-cells, including defects in glucose
transporter expression, KATP channel function, and prohormone-processing enzymes [44].
The strategies for differentiation of hESCs into insulin-producing cells also have been
demonstrated by many research groups. They demonstrated that the insulin-producing cells
are expressed the markers associated with pancreatic β-cell differentiation pathway, able to
produce and secrete insulin in response to glucose concentration [42, 45–49]. The spontane‐
ous differentiation of insulin-producing cells can also be observed with undifferentiated hESCs
colonies when hESCs are propagated on a feeder layer of MEFs [45]. It has been demonstrat‐
ed that in vitro differentiation in suspension culture results in the formation of discrete
embryoid bodies (EBs) and a more consistent pattern of nestin-positive progenitors which
possibly are insulin-producing progenitors [49] (Figure 1).
Figure 1. Summary of in vitro differentiation protocol for derivation of insulin-producing cells from hESCs. The
directions of hESCs into insulin-producing cells are based on the variety of experimental approaches. During in vitro
differentiation hESCs, the procedures were performed through a multistep including adherent culture, suspension cul‐
ture, and hanging drop for generating the precursor cells. Cells grown under adherent conditions displayed a pleio‐
tropic pattern with numerous morphologies. In addition, the differentiation of hESCs into insulin-producing cells was
successfully induced by the nestin-positive progenitor-based and definitive endoderm-based protocols [43–46, 49].
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Recently, it has been shown that maturation of stem cell into beta-cells can be driven by the
expression of peptide hormone called urocortin 3 which also served as islet cell maturation
marker [50]. In addition, the scalable differentiation protocol also able to generate several
millions of glucose-responsive β-cells from hESCs [51]. Interestingly, it has been revealed that
acceleration of Cdk4-cyclin D complex in the cell cycle of hESCs also play a potential key role
in cell fate decision of hESCs differentiation into insulin-producing cell [52].
Although several authors achieved to demonstrate the rapid progress for possible treatment
of diabetes using insulin-producing cells generated from hESCs, there are some crucial aspects
need to be concerned. Based on this regard, the culture should be performed in xeno-free
system in order to further develop potential medical applications. Moreover, the contamina‐
tion of undifferentiated hESCs in the culture of insulin-producing cell induction needs to be
removed before it can be applied for therapeutic purposes to eliminate the teratoma forma‐
tion. The immune rejection aspect is also need to be assessed. For examples, during differen‐
tiation stage, the major histocompatibility complex (MHC) is up-regulated, leading to the non-
self-proteins expression on the graft cells which may result in immune rejection of the graft in
the absence of immunosuppressive therapy [25]. In addition, the expression of high level of
telomerase activity can lead to teratoma formation after injection which should be noted [53].
Furthermore, prolonged growth of hESCs and differentiation of these cells into any stages of
beta-cells development in vitro may also cause chromosomal aberrations. Therefore, com‐
plete characterization of hESC lines, insulin-producing cells, or other pancreatic cell stages that
will be applied for therapeutic purposes need to be well analysis, for example, their molecu‐
lar status, a continuous genetic, and chromosomal features.
2.4. Transplantation of hESC-derived insulin-producing cells
In order to gain insights into the human condition, the function of hESC-derived insulin-
producing cells should be achieved in vivo. Also, many research groups have tried to trans‐
plant insulin-producing cells derived from hESCs into animal models of diabetes mellitus. For
instance, the transplantation of hESC-derived ILC under the kidney capsule of streptozoto‐
cin (STZ)-induced diabetic immuno-incompetent mice exerted functional benefits. The grafted
cells continued to contain cells that were shown the ability to secrete human C-peptide in
response to an oral bolus of glucose. In addition, the transplanted ILCs could promote the
mean survival of recipients as compared to controls, which were transplanted with human
fibroblast cells [54]. Hua and colleagues reported the protocol for differentiating hESCs into
pancreatic insulin-producing cells and transplanted the cells into severe combined immuno‐
deficient (SCID)/non-obese diabetic (NOD) mice to assess graft survival and function. The
terminally differentiated cells were glucose-responsive and expressed C-peptide, similar to
pancreatic islets. When transplanted into the epididymal fat pad of SCID/NOD mice, these
cells were capable of correcting hyperglycemia for ≥ 8 weeks. Notably, none of the treated
animals developed tumors [55]. Alternatively, the function of pancreatic endoderm or
pancreatic progenitors derived from hESCs has been observed following transplantation into
diabetic models. Recent study has demonstrated that the engrafted hESC-derived pancreatic
endoderm generated functional endocrine cells when implanted in the epididymal fat pad of
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SCID/Beige mice. The grafted cells exhibited appropriate expression of pancreatic transcrip‐
tion factors, expressed prohormone-processing enzymes, and contained mature, homogene‐
ous endocrine secretory granules. Moreover, the engrafted hESC-derived endocrine cells
regulated glucose homeostasis in the host by synthesized and released insulin in response to
glucose levels [56]. Rezania et al. provided evidence that hESC-derived pancreatic progeni‐
tor cells successfully matured into functional islets in vivo and controlled glycemia of STZ-
treated immunodeficient mice. The study demonstrated that the differentiation protocol has
generated a highly enriched Pdx1+ pancreatic progenitor cell population in vitro without cell
sorting. These progenitor cells were remarkably developed similar to human fetal pancreas
development and resulted in the formation of insulin-producing cells that closely resembled
matured human β-cells. The implanted cells contributed to protect mice against STZ-in‐
duced diabetes with robust glucose-stimulated human C-peptide secretion in vivo [57].
Currently, cellular encapsulation has been provided immunoprotection in host with the
potential to reduce or eliminate the need for chronic immunosuppression. In a recent study,
Kirk and colleagues used a bilaminar device (Theracyte) to investigate the kinetics of cellu‐
lar engraftment and the maturation dynamics of hESC-derived pancreatic epithelium (PE).
They found that in vitro derived hESC-PE cells generated through glucose-responsive insulin-
producing cells inside an encapsulation device with no increase in cell mass and without cell
escape. The encapsulated hESC-derived PE exhibited full physiological function in vivo and
resulted in amelioration of alloxan-induced diabetes following implantation [58]. Despite
promising findings in a test of therapeutic potential, both safety and efficacy of the hESC-based
therapy for insulin-dependent diabetes must be further investigated.
3. Induced pluripotent stem cells
3.1. The generation of iPSCs
The induced pluripotent stem cells (iPSCs) also provided an alternative approach to pro‐
duce autologous cell-based therapy (Figure 2). The iPSCs have been shown the properties
similar to hESCs including morphology, self-renewal capacity, gene expression profiles, and
retained a normal karyotype. The differentiation potential of these cells would allow research‐
ers to study disease mechanisms, drug screening and provide another autologous cell sources
for transplantation [59–61].
Based on the knowledge of transcriptional regulators that maintain the stem cell state,
researchers have been developed a technique that can be reprogrammed adult cells into
pluripotent stage. In 2006, Takahashi and Yamanaka discovered that the introduction of four
transcription factors (Oct4, Sox2, c-Myc, and Klf4) could induce pluripotency in mouse
embryonic or adult fibroblasts. These iPSCs exhibited the morphology and growth proper‐
ties of ESCs and expressed ESC marker genes. The resultant cells resulted in tumors contain‐
ing a variety of tissues from all three germ layers when transplantation into nude mice.
Consequently, Yu and colleagues designed a reprogramming strategy in which a set of four
factors (Oct4, Sox2, Nanog, and Lin28) were sufficient to induce pluripotency in human
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somatic cells. These cells displayed normal karyotypes, expressed telomerase activity,
expressed the hESC surface markers/genes, and maintained the developmental potential to
differentiate into advanced derivatives of all three primary germ layers [62]. Additionally, it
has been found that the miR-302 family is specifically expressed in undifferentiated ESCs. The
miR-302 has a role in regulating ESC pluripotency and differentiation [63, 64]. Also, several
studies have demonstrated that miR-302 can directly reprogram somatic cells. Lin et al.
reported that miR-302 inhibits stem cell tumorigenicity by enhancing G1 phase arrests
pathway [65]. This evidence suggests that the miR-302-reprogrammed iPSCs may provide the
potential applications of iPSC technology.
Figure 2. Induced pluripotent stem cells (iPSCs) and the potential use in regenerative medicine. Adult cells or so‐
matic cells can be reprogrammed into pluripotent stem cells by introducing a specific set of reprogramming factors.
These iPSCs can then be differentiated to specialized cell types, which can be used as a clinical tool for disease model‐
ing, drug development/drug toxicity tests, gene therapy, and cell-based therapy.
The approach to reprogram somatic cells involved the use of genome-integrating retrovirus‐
es to transfer transcription factors. However, the usage of integrating retroviral vector has
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major limitation due to the potential risk relating to tumor formation. Thus, researchers have
also used the different strategies with non-integrating system that provided the solution to
make it clinically applicable [66]. Although the reprogramming efficiencies with non-integrat‐
ing method are lower (~0.001%) than those achieved with integrating method (0.1–1%), this
method increases the safety of generating and using iPSCs [67]. Alternative methods have been
developed to avoid genetic modification as the reprogramming proteins, or mRNA was
delivered directly into the cells. This has been successfully demonstrated that high reprog‐
ramming efficiencies, however, can be more complicated to perform [66].
Interestingly, iPSCs technology has been possible to create disease-specific cells from individ‐
ual patients that could be analyzed the disease pathology, provided treatment methods and
drug development [65]. In addition, it has been documented that iPSCs can be generated into
the desired cell types, which hold great promise for treating many diseases. There have been
reported in iPSC-derived cells in clinical applications in several types of disease including
neurological, immune system, endocrinology/metabolism, muscle skeletal, genetic, hemato‐
logical, and inherited liver disease [68].
3.2. Differentiation of iPSCs into insulin-producing cells and transplantation
The achievement of hESCs differentiation into insulin-producing cells has raised up the
possibility of generation of iPSCs-derived insulin-secreted cells by adopted the same proto‐
cols that have been used in hESCs works into iPSCs studies with or without modification the
protocols. Recently, researchers have also been differentiated iPSCs into functional insulin-
producing cells in vitro. The resulting cells expressed pancreatic lineage-related genes, which
further normalized blood glucose levels and restored insulin secretion when transplantation
into diabetic models. As such, the potential of iPSC-derived insulin-producing cells is also
considered as useful tool for diabetes therapy [69–72]. Currently, it has been demonstrated
that iPSCs differentiated into posterior foregut and endocrine cells can be transplant and
secrete insulin in immunodeficient mouse model [73].
These findings suggested that iPSC-derived insulin-producing cells will provide a potential
therapeutic source for treating diabetes. It should be noted that iPSC technology is a possi‐
ble alternative to induce patient-derived iPSCs for autologous cell transplantation therapy.
3.3. The limitations of hESCs and iPS cells
The potential application of hESCs has been extensively studied due to their high differentia‐
tion capacity. However, the use of hESCs to generate functional cells raises the problems
associated with technical limitations and ethical issues. These limitations including
(1) the ethical controversies associated with the use of fresh human embryos, (2) developing
xenogeneic products-free culture systems both for culturing hESCs and insulin-producing cell
differentiation, (3) teratoma formation has become a critical obstacle for the therapeutic
applications of hESCs, and (4) destruction of transplanted cells in vivo.
The ethical controversies represent another issue associated the use of fresh human embryos.
There is concern about guidelines on the use of fresh embryos as a source of new hESC lines.
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In this regard, induced pluripotent stem cells (iPSCs) technology provides a solution to the
ethical debate surrounding hESCs since it does not require both the destruction of an em‐
bryo and the use of human oocytes [74].
It is generally believed that highly purified progenitors or terminally differentiated cell types
derived from hESCs results in prevention of teratoma formation [75]. While subpopulations
of hESCs have been characterized by the expression of distinct surface markers, their fates have
provided a valuable tool for generating tissue-specific reagents for cell-based therapy [76].
Moreover, the combined gene transfer/hESCs therapies can generate a pure population of
genetically modified differentiated cells with the selection using lineage-specific markers [77].
Furthermore, the encapsulation procedure has the potential to prevent the formation of
tumors [78].
The possible destruction of transplanted hESCs derivatives by the patient’s immune system
should also be considered before the transplantation of these cells. Some solutions to pre‐
vent the rejection of hESC-derived cells are the use of hematopoietic chimerism for tolerance
induction and the creation of universal donor cell line [79, 80] and encapsulation technology
[81].
The great promise of iPSCs is based on their properties of self-renewal capacity and differen‐
tiation into specialized cell types. In addition, the possibility to obtain patient-specific or
disease-specific pluripotent stem cells is a promising approach for medical applications.
Moreover, iPSCs are not associated with ethical issues as hESCs regarding the use of human
oocytes or embryos in research. However, there are still some limitations including inade‐
quate cell number, immune rejection, and teratoma formation upon transplantation.
3.4. Encapsulation technology: a power tool for hESCs and iPS cells applications
In the context of therapeutic applications, the encapsulation technology represents a power‐
ful tool toward the implementation of hESCs and iPSCs in clinical and industrial applica‐
tions. Generally, there are two types of encapsulation technologies available at the present time
including microencapsulation and macroencapsulation. Microencapsulation technology aims
to generate a small size semipermeable bag which popularly made of hydrogel polymers to
cover small group of cells. On the other hand, macroencapsulation technology has been used
to generate semipermeable membrane and hydrogel sheets to hold large scale cell quantity. In
the aspect of oxygen diffusion into the encapsulated environment, the microencapsulated
sphere allows higher oxygen diffusion capacity than macroencapsulated sphere.
In stem cell research, the encapsulated hESC results in high expansion ratio and high cell
recovery yields after cryopreservation. This method also improves the culture of hESC
aggregates by protecting cells from hydrodynamic shear stress, controlling aggregate size, and
maintaining cell pluripotency [82]. It has been demonstrated that hESCs encapsulated in
alginate hydrogels maintain the undifferentiated state and retain their pluripotent capabili‐
ties without any enzymatic treatment, mechanical expansion, or manipulation in a feeder-free
environment. This approach is well-suited for providing automated culture scale-up process
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and the opportunity of long-term culture, feeder-free, and non-labor-intensive culture of
hESCs [83].
Alginate encapsulation systems have been shown to support the ability of ES cells to differ‐
entiate into specific cell types. The researchers use an alginate encapsulation process for the
proliferation and growth of mESC aggregates, which further supports the differentiation of
insulin-positive cells from mESCs [84]. In addition, the other group demonstrates 3D model
to culture and differentiate hESCs that are encapsulated in calcium alginate microcapsules.
This system promotes cellular interactions that are essential for both maintaining pluripoten‐
cy and differentiation. In addition, encapsulated hESCs are separated from feeder cells during
the process of differentiation, which mimics in vivo microenvironment and bypass the EBs
formation step in a controlled manner. Thus, this 3D culturing of hESCs using alginate
microcapsules may be useful for direct differentiation of hESCs toward particular cell types
and also has potential for immunoisolation and prevention of teratoma formation of hESCs
during transplantation [85].
Cell encapsulation has been proposed to be a solution for treatment of diabetes since it
potentially allows the cell protection from host immune system by a concept of immunoiso‐
lation. In particular, the microcapsules of islets provide a delicate balance of characteristics
including physical strength, immunocompatibility, and selective permeability that will block
large immune components. Additionally, its membrane allows the passage of smaller
molecules such as oxygen, glucose, water, and insulin [86]. In addition, encapsulated islets in
a biocompatible alginates have protected the islets against immune rejection, which is
confirmed by prolonged survival of encapsulated islet allografts up to 200 days [87].
Furthermore, Schneider et al. [88] have developed a microcapsule system that protects adult
rat and human islets against xenogeneic rejection in immunocompetent diabetic mice without
immunosuppression.
3.5. Mechanism of insulin secretion by glucose stimulation
Glucose in the blood is the strong stimulator for the insulin secretion from the islets pancre‐
atic beta cells. Besides glucose, amino acids, ketones, some nutrients, gastrointestinal pepti‐
des, and neurotransmitters can also influences the insulin secretion from the beta cells. The
glucose-regulated insulin secretion is the complex process and involved several key proteins.
Normally, the blood glucose level of more than 70 mg/dl (3.9 mmol/L) enhances insulin
production by promoting protein translation and processing. This stimulatory process starts
with the binding of glucose to the GLUT2 glucose transporter on the cell membrane of the beta
cells. The cytoplasmic glucose is subjected to metabolic process by the action of glucokinase
to produce glucose-6-phosphate, which is the rate-limiting step of insulin secretory pathway.
Further glycolysis of glucose-6-phosphate finally produces ATP, which is the key molecule for
inhibition of the ATP-sensitive K+ channel protein on the beta cell membrane. The inhibition
of ATP-sensitive K+ channel protein results in beta cell membrane depolarization. This
depolarization of the cell membrane induces the opening of voltage-dependent calcium
channels with subsequently influx of calcium. High level of cytoplasmic calcium will drive the
secretion of insulin from the secretory granules. Insulin secretory profile shows pulsatile
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pattern of insulin release, with small bursts occurring about every 10 min. Superimposed upon
greater amplitude oscillations of about 80–150 min. This glucose-induced insulin secretion can
be enhanced by incretins, released from the neuroendocrine cells of the gastrointestinal tract
following food ingestion (Figure 3) [89, 90]. However, the mechanism of secretion of insulin
with regard to the concentration of glucose from insulin-producing cells derived from hESCs
and iPSCs remains unclear.
Figure 3. Glucose-stimulated insulin secretion of pancreatic beta cells. In the unstimulated state, the cell ATP-sensi‐
tive potassium channels are open, keeping a resting membrane potential of approximately −65 mV. (A) Following the
uptake of glucose and its metabolism by glucokinase, (B) an increase in the intracellular ATP–ADP ratio results in
closure of ATP-sensitive potassium channels, (C) depolarization of the cell membrane and subsequent opening of volt‐
age-dependent Ca2+ channels. (D) The resulting increase in cytosolic Ca2+ concentration triggers insulin release [90].
4. Conclusion
To date, the researchers have discovered a process that can generate insulin-producing cells
from both hESCs and iPSCs. The step toward generating the insulin-producing cells re‐
quired a differentiation protocol in a manner that mimics differentiation in vivo. In order to
promote the mature cells, the expression of a key transcription factors should be achieved in
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vitro. Based on these studies, the differentiation processes were successful at generating
functional insulin-producing cells in vitro. Although there may be some concerns about hESC
and iPSCs research, there are emerging evidences that both hESCs and iPSCs were success‐
fully engrafted, secreted insulin, and regulated blood glucose level in animal models. The
encapsulation technology also improves the transplantation efficiency by prevention of
encapsulated cells from immune destruction, reduce risks of cancer generation by stem cells,
and decrease chronic immunosuppression health risks.
However, current prospects for hESC- and iPSCs-based therapy for diabetes treatment still be
requires to investigated further more in early phase and subsequent trials in animal models to
generate more safety and effective treatment prior to apply to human therapy.
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